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FolateThe proton-coupled transporter (PCFT) mediates intestinal folate absorption and folate transport from blood
across the choroid plexus. The membrane topology of PCFT has been deﬁned using the substituted cysteine
accessibility method; an intramolecular disulﬁde bond between the Cys 66 and 298 residues, in the ﬁrst and
fourth extracellular loops, respectively, is present but not essential for function. The current report describes
Lys 422 mutations (K422C, K422E) that have no effect on transport activity when introduced into wild-type
PCFT but result in amarked loss of activity when introduced into a Cys-less PCFT which is otherwise near-fully
functional. The loss of activity of both mutant PCFTs was shown to be due to impaired protein stability
and expression. Additional studies were conducted with the K422C mutation in Cys-less PCFT. The impact of
re-introduction of one, two, three or ﬁve, Cys residues was assessed. While there were some differences in the
impact of the different Cys residues re-introduced, restoration was attributed more to a cumulative effect
rather than the speciﬁc role of individual Cys residues. Preservation of the Cys66–Cys298 intramolecular
disulﬁde bond was not required for stability of the K422C protein. These observations are relevant to studies
with Cys-less transporters utilized for the characterization of proteins with the substituted cysteine
accessibility method and indicate that functional defects detected in a Cys-less protein, when the tertiary
structure of the molecule is stressed, are not necessarily relevant to the wild-type protein.MTX, methotrexate; PCFT, the
folate malabsorption; SCAM,
+1 718 430 8550.
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The proton-coupled folate transporter (PCFT1), recently cloned, is
the mechanism by which folates are absorbed across the apical brush-
border membrane of the proximal small intestine and is required for
transport of folates across the blood–choroid plexus–cerebrospinal
ﬂuid barrier [1]. Both processes are defective in the rare autosomal
inherited disorder, hereditary folate malabsorption (HFM) [2,3],
which was shown by this laboratory to be due to mutations in the
pcft gene [1,4–7] and subsequently reported by other groups [8–10].
While proton-coupled, this transporter is also operational in the
physiological pH range where it has a particularly high afﬁnity for the
new-generation antifolate, pemetrexed [11], currently approved for
the treatment of mesothelioma and non-squamous, non-small cell
lung cancer [12,13]. Most recently, antifolate compounds speciﬁcally
designed for transport by PCFT have been synthesized [14].
This laboratory recently reported on the PCFT topological structure
using the substituted cysteine-accessibility method (SCAM) [15]. This
procedure requires that the Cys-less protein retain nearly full activityand is based on the reintroduction of Cys residues, individually, in
intracellular and extracellular loops followed by assessment of their
accessibility by a membrane impermeant reagent in the presence and
absence of membrane permeabilization [15]. This approach, along
with localization of its C- and N-termini [16,17], established PCFT to
have twelve transmembrane domains with its N- and C-termini
directed to the cytosol. An intramolecular disulﬁde bond between
native Cys residues 66 and 298was also identiﬁed, a post-translational
modiﬁcation that does not appear to inﬂuence function [15].
Within the context of these studies, along with an assessment of
the role of Lys residues in PCFT function, the observation was made
that replacement of the fully conserved Lys at position 422 with Cys in
the wild-type protein had no functional consequence. However, the
same substitution in the Cys-less PCFT resulted in an almost complete
loss of activity. The current study explores the basis for these ﬁndings
and demonstrates the impact that Cys residues play, cumulatively, in
stabilizing the PCFT protein independent of their role in the formation
of disulﬁde bonds.
2. Materials and methods
2.1. Key chemicals, antibodies and cell lines
[3′,5′,7-3H(N)]-MTX was obtained from Moravek Biochemicals
(Brea, CA). EZ-Link Sulfo-NHS-LC-biotin and streptavidin-agarose
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Scientiﬁc (Pittsburg, PA), respectively. Anti-HA antibody (H6908) was
purchased from Sigma (St. Louis, MO); anti-actin antibody (4967) and
anti-rabbit IgG-HRP conjugate were obtained from Cell Signaling
Technology (Danvers, MA). HeLa R1-11 cells that lack expression of
both the reduced folate carrier and PCFT, due to deletion of the former
gene and methylation of the latter pcft promoter [18,19] were
maintained in RPMI-1640 medium supplemented with 10% fetal
bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin.
Cry-preserved HeLa R1-11 cells were thawed regularly to assure that
PCFT expression was absent or minimal [20].
2.2. Site-directed mutagenesis to generate PCFT mutants
All mutations were introduced into a C-terminus HA- (hemagglu-
tinin)-tagged human wild-type- or Cys-less PCFT expression vector
[15]. A single mutation was introduced using the QuikChange® II XL
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA), whereas a
combination of mutations was generated with the QuikChange®
Multi Site-DirectedMutagenesis Kit (Stratagene, La Jolla, CA). For both
methodologies, a primer contained the designated mutation ﬂanked
by twelve nucleotides. For some mutations, a temperature (50 or
55 °C) lower than the standard annealing temperature of 60 °C was
required. The coding region of the ﬁnal expression vector was veriﬁed
by automated sequencing in the Albert Einstein Cancer Center
Genomics Shared Resource.
2.3. Transient transfection
For transport studies, HeLa R1-11 cells were routinely seeded into
20 ml Low Background glass scintillation vials (Research Products
International Corporation, Prospect IL) at 0.35 million cells per vial.
For surface labeling experiments, HeLa R1-11 cells were grown in
6-well plates at a density of 0.6 million cells per well. In both
cases transfections were performed 2 days later with Lipofectamine
2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's
protocol. Transport and labeling assays were conducted 2 days after
transfection.
2.4. Transport measurements
Cells were washed twice with HBS (20 mMHEPES, 5 mMdextrose,
140 mM NaCl, 5 mM KCl, 2 mM MgCl2, pH 7.4) and incubated in the
same buffer at 37 °C for 20 min. The incubation buffer was then
aspirated and transport was initiated by the addition of 0.5 ml of pre-
warmed (37 °C) MBS (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM
MgCl2, pH 5.5) containing the 0.5 μM [3H]MTX. Uptakewas carried out
at 37 °C over 1 min and stopped by the addition of 5 ml ice-cold HBS.
Cells were washed three times with ice-cold HBS and dissolved in
0.5 ml of 0.2 M NaOH at 65 °C for 40 min. Radioactivity in 0.4 ml
of lysate was measured on a liquid scintillation spectrometer and
normalized to protein levels obtained with the BCA Protein Assay
(Pierce, Rockford, IL).
2.5. Cell surface biotinylation assay
This assay was described previously [21]. Brieﬂy, cells were
washed twice with PBS (pH 8.0) and labeled at room temperature
with EZ-Link Sulfo-NHS-LC-Biotin, which reacts speciﬁcally with
primary amine groups, at a concentration 1 mg/ml in PBS (pH 8.0) for
30 min. Cells were washed twice in PBS and treated with 0.7 ml
hypotonic buffer (0.5 mMNa2HPO4, 0.1 mM EDTA, pH 7.0) containing
protease inhibitor cocktail (Roche, Indianapolis, IN) on ice for 30 min.
The cells were then detached from the plates with disposable cell
lifters and centrifuged at 16,000×g and 4 °C for 5 min. The pellet was
then resuspended in 0.4 ml lysis buffer (50 mM TRIS-base, 150 mMNaCl, 1% NP40, 0.5% sodium deoxycholate, pH 7.4) and mixed on a
rotisserie shaker for 1 h at 4 °C. A 25-μl portion (identiﬁed as “crude
membrane”) was collected and stored in a freezer. The remaining
crude membrane fraction was centrifuged at 16,000×g and 4 °C for
15 min and the supernatant was mixed on a rotisserie shaker
overnight at 4 °C with 50 μl of streptavidin agarose that was pre-
washed three times with the lysis buffer. The agarose beads were
washed four times with 0.5 ml lysis buffer, each with a 20 min mix on
a rotisserie shaker at 4 °C. The precipitated proteins were released
from the beads by heating at 95 °C for 5 min in 2× SDS-PAGE sample
loading buffer containing dithiothreitol.
2.6. Western blot analysis
Samples were resolved on standard 12.5% SDS-PAGE. The
precipitated proteins (released from beads as described in the
previous section) were loaded directly on gels while the crude
membrane fraction was mixed (1:1) with dithiothreitol-containing
2× SDS-PAGE sample loading buffer at room temperature before
loading on the gels. After SDS-PAGE, proteins were transferred to
Amersham Hybond membranes (GE Healthcare, Piscataway, NJ) and
were blocked with 10% dry milk in TBST (20 mM Tris, 135 mM NaCl,
1% Tween 20, pH 7.6) overnight. For crude membrane samples, the
blots were probed with anti-actin antibody (1:2000 in TBST, 0.1%
milk) then stripped in 100 mM β-mecaptoethanol, 2% SDS, 62.5 mM
Tris–Cl at pH 6.7 and re-probed with anti-HA antibody (1:4000 in
TBST, 0.1% milk). For precipitated samples, blots were probed directly
with anti-HA antibody. After application of the ﬁrst antibody, the blots
were incubated with anti-rabbit IgG-HRP conjugate (1:5000 in TBST).
The blots were developed with Amersham ECL Plus reagent (GE
Healthcare, Piscataway, NJ) and exposed to autoradiography ﬁlm
(Denville Scientiﬁc, Metuchen, NJ).
3. Results
3.1. Effects of substitutions of lysine 422 on PCFT function
Human PCFT contains eleven Lys residues as indicated in Fig. 1.
However, eight (Lys 10, 235, 238, 262, 265, 302, 323, 445) are not
conserved among 10 species (human, monkey, cow, horse, rat, mouse,
dog, opossum, Xenopus and zebra ﬁsh) excluding critical roles in PCFT
function. Only Lys 378 and 422 are fully conserved (identical) while
Lys 381 is semi-conserved (Arg is at this position in cow and
opossum). Previous studies indicated that neither Arg 378 nor Arg 381
is required for function [21]. As indicated in Fig. 2A, replacement of Lys
422 in wild-type PCFT with polar Cys (K422C-WT), like-charged Arg
(K422R-WT), non-polar Ala (K422A-WT) or opposite-charged Glu
(K422E-WT) did not affect PCFT activity. Hence, Lys 422 is fully
replaceable. The sufﬁx “WT” in the mutant names indicates that the
mutation was introduced into WT PCFT.
During the course of another study using SCAM to deﬁne the
membrane topology of PCFT, Cys residues were individually substituted
for residues in loops of the transporter in which all seven native Cys
residueswere replacedwith Ser ( Cys-less or CL-PCFT).When theK422C
mutation was introduced into the CL-PCFT (K422C-CL), activity was
markedly reduced to 10% that ofWT-PCFT(Fig. 2B). The sufﬁx “CL” in the
mutant names indicates that themutationwas introduced into CL-PCFT.
Substitution of Lys 422 with Ala or Arg in CL-PCFT led to only a modest
reduction in activity (54%or 38% respectively) as compared toWT-PCFT.
However, replacement of K422 with Glu resulted in a loss of ~90% of
activity.
The levels of expression of the K422C-CL PCFT mutant protein in
the crude membrane fraction and accessible at the plasma membrane
were markedly decreased as compared to WT-PCFT, K422C-WT, or
CL-PCFT (Fig. 2C). Expression of the K422E-CL mutant was also barely
detectable in the crudemembrane fraction or at the plasmamembrane
Fig. 1.Membrane topology of PCFT and localization of Cys and Lys residues. Membrane topology of human PCFT was established in a previous study [15]. The start and end of each
transmembrane domain is marked by arrows and residue numbers. All seven native cysteine residues (orange) were replaced with Ser in a CL-PCFT. All eleven lysine residues are
indicated by green circles; most are located either in loops or boundaries of loops and transmembrane domains. EL, extracellular loop; IL: intracellular loop.
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detectable; however, the reduction in protein was greater than the
reduction in activity as compared to CL-PCFT (Fig 2D). Hence, the
adverse effects of substitutions at Lys 422 of CL-PCFT were due to
impaired protein stability and expression.Fig. 2. Effects of mutations at Lys 422 in wild-type and CL-PCFT. [3H]MTX inﬂux was assess
constructs in which the K422mutations were introduced intoWT-PCFT (Panel A) or into CL-P
1 min; the data is normalized to the wild-type PCFT level indicated as 100%. Data are the mea
fraction and biotinylated at the plasma membrane is indicated for the K422C-CL mutant (P
loading control for the crude membrane fraction. The Western blots are representative of a3.2. Impact of the disulﬁde bond between Cys 66 and Cys 298 on the
stability of the K422C PCFT mutant
There is a disulﬁde bond located between Cys66 and Cys298 in the
ﬁrst and fourth extracellular loops, respectively, that is not requireded in HeLa R1-11 cells, that lack endogenous folate transporters, transfected with PCFT
CFT (Panel B). TheMTX concentration was 0.5 μM; the pH 5.5. Uptake was assessed over
n±SEM from three independent experiments. PCFT expression in the crude membrane
anel C) and K422A-CL, K422R-CL as well as K422E-CL mutants (Panel D). Actin is the
t least two separate experiments.
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for stability of the K422 mutants, Cys66 and Cys298 were re-
introduced into the K422C-CL PCFT mutant, the least active of the
CL-PCFT mutants. As indicated in Fig. 3A, MTX inﬂux mediated by this
mutant (K422C/S66C/S298C-CL) was 72% that of CL-PCFT and six-fold
higher than K422C-CL. This partial restoration of activity correlated
with PCFT expression in the crude membrane fraction and accessible
at the plasma membrane (Fig. 3B). Hence, the presence of Cys 66 and
298 neutralized the negative impact of the K422C mutation.
To determine whether the Cys66 and Cys298 residues as well as
the bond between them are absolutely required to negate the effect
the K422Cmutation, Cys66 and Cys298 were simultaneously replaced
with Ser in the K422C-WT background to obtain the K422C/C66S/
C298S-WT in which the other ﬁve native cysteine residues were
intact. As indicate in Fig. 3A, transport activity mediated by K422C/
C66S/C298S-WT was essentially the same as that of K422C/S66C/
S298C-CL PCFT. As indicated in Fig. 3B, expression of 422C/C66S/
C298S WT-PCFT protein was comparable to, or slightly greater, than
that of K422C/S66C/S298C-CL PCFT. Hence, it is not the presence of the
Cys 66 and Cys 298 residues, per se, or the disulﬁde bond between
them, that restored activity for the K422C mutant in CL-PCFT, rather it
was the presence of added Cys residues that was the important factor
as indicated by the high level of activity and expression associated
with the mutant construct in which these residues were absent, but
the other Cys residues in WT PCFT remained.Fig. 3. Effects of additions of Cys66 and Cys298 to CL-PCFT, and substitutions of these
residues with Ser in WT-PCFT, on protein expression and function. Panel A: MTX inﬂux
was assessed in transfectants as described in Fig. 2 and indicated as percentage of
WT-PCFT. Data are themean±SEM from three independent experiments. Panel B: PCFT
expression in the crude membrane fraction and biotinylated at the plasma membrane.
Actin is the loading control for the crude membrane fraction. The Western blots are
representative of two separate experiments.Finally, conﬁrming the lack of importance of the Cys66–Cys298
disulﬁde bond in the stability of the K422C/S66C/S298C-CL, transient
transfectants expressing this mutant along with WT-PCFT were
treated with β-mercaptoethanol, a process known to disrupt the
disulﬁde bond in WT-PCFT [15]. Based on three independent
experiments, there was no signiﬁcant change in MTX inﬂux
(0.5 μM) conducted at pH 5.5 over 1 min after β-mercaptoethanol
incubation, either for the K422C/S66C/S298C-CL mutant (treated-
24.3±0.3 vs. control-26.1±2.4 nmol/mg protein, P=0.49 from
paired t-test) or for WT-PCFT (treated-41.6±3.2 vs. control-48.3±
3.7 nmol/mg protein, P=0.11 from paired t-test). Therefore, if a
disulﬁde bond indeed forms between Cys 66 and C298 in the K422C/
S66C/S298C-CL mutant as in WT-PCFT, it was apparently not
important for function of the mutant.
3.3. The cumulative effects of Cys residues in the stabilization of the
K422C-CL PCFT
As indicated above, the K422C/C66S/C298S-WT mutant, in which
ﬁve native cysteine residues (Cys 21, 151, 229, 328 and 397) were
intact, sustained 60% of WT-PCFT activity and was expressed at a level
similar to CL-PCFT. In the next series of experiments, the role of each
of the remaining ﬁve Cys residues, or a combination of these residues,
in sustaining stability of the K422C-CL PCFT was assessed. To accom-
plish this, a spectrum of mutants, in which K422Cwas always present,
along with a variable number of Cys residues, was generated by a
single multi-site-directed mutagenesis. Two additional mutants in
which Cys 66 or Cys 298 were reintroduced into K422C-CL PCFT were
generated separately. As indicated in Fig. 4A, the activities of 15
mutants, all of which had the K422C substitution, were assessed and
compared to K422C-CL and WT-PCFT. Five mutants contained only
one Cys residue, ﬁve contained two Cys residues, ﬁve contained three
Cys residues, and one contained ﬁve Cys residues. There was a general
correlation between the number of Cys residues and function. The
greater the number of Cys residues, the greater the transport function.
This relationship becomes clear if mutants which represent consec-
utive additions of Cys residue are compared (+C151 vs. +C151+
C397 vs. +C151+C229+C397) and (+C21 vs. +C21+C397 vs.
+C21+C151+C397). There was a large increase in function when
K422C mutants containing one Cys residue were compared to
mutants containing two Cys and when mutants containing two, are
compared to mutants containing three, Cys residues. There was no
further increase in activity between constructs containing the three
added residues and the one containing ﬁve Cys residues. However, not
all Cys residues contributed equally to maintaining activity of these
mutants. For example, Cys 229 and 298 were more efﬁcient than Cys
21, 66, 151 when a single Cys residue was compared. Cys 21 and 151
were also not as efﬁcient as Cys 229, C328 and 397 when a com-
bination of two Cys residues were compared.
Preservation of PCFT protein expression correlated with preser-
vation of PCFT function. As indicated in Fig. 4B, themutants containing
the C151 or C151+C397 additions, with only a low level of function,
expressed only low levels of protein. While the mutant containing
three added Cys residues (C151+C397+C229) expressed higher
levels of protein, comparable to the mutant containing ﬁve added Cys
residues (+C21+C151+C229+C328+C397), both had high and
comparable levels of function.
4. Discussion
SCAM is widely used in deﬁning membrane topology and the role
of speciﬁc residues or domains in transport function [22]. The key
requirement for thismethodology is retention of functionwhen all Cys
residues are replaced, in most cases, with Ser. Indeed, the majority of
Cys-less transporters are functional as is the case for cysteine-less PCFT
[15]. However, in some transporters Cys residues are irreplaceable,
Fig. 4. Comparison of function and expression of PCFT mutants in which a variety, and variable number, of Cys residues have been re-introduced into the K422C-CL. Panel A: MTX
inﬂux was assessed in transfectants as described in Fig. 2 and is indicated as percentage ofWT-PCFT. Data are the mean±SEM from three independent experiments. The mutants are
grouped according to the number of Cys residues and arranged from low to high activity within each group. All mutants contain the K422C mutation. “+C66” indicates a mutant in
which native Cys66was reintroduced into K422C-CL; +C151+C397” indicates amutant in which both native Cys 151 and 397were simultaneously introduced into K422C-CL. Other
mutants are designated in the same fashion. Panel B: PCFT in the crude membrane fraction and accessible at the plasma membrane. Actin is the loading control for the crude
membrane fraction. The Western blot analysis is representative of two separate experiments.
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formation of a functionally important disulﬁde bond between Cys 180
and 329 residues [23] and the human vesicle monoamine transporter
(VMAT2), due to a critical disulﬁde bond between the Cys 126 and 333
residues [24]. In SCAM, Cys resides are introduced into the Cys-less
transporter at speciﬁc sites following which function of these mutants
is assessed, and accessibility of these Cys residues to sulfhydryl
reagents is probed. However, whenever a resulting mutation causes
functional impairment, it is usually assumed that the residue has a
comparable role in thewild-type transporter. The results in this report
clearly indicate that functional defects detected in a Cys-less protein
may not be extrapolated to the wild-type protein.
The molecular basis for the functional impairment of the various
K422mutants in CL-PCFTwas the lack of protein expression,most likely
due to impaired protein folding and stability. An attempt was made to
determine whether speciﬁc Cys residues were responsible for the
preservation of protein stability. Two obvious candidates were the
Cys66 and Cys298 residues that form an intramolecular disulﬁde bond
in the WT-PCFT and, while this bond is not required for function in
that setting, it was possible that the bond was required in a carrier
structurally stressed by a drastic mutation. Indeed, simultaneous
reintroduction of these two Cys residues in the K422C-CL PCFT
preserved a majority of protein expression and function. However,
abrogationof this bondwithβ-mercaptoethanol didnot alter the impact
of these added residues and substitution of both residueswith Ser in the
K422C-WT PCFT did not result in a loss of protein and function. Hence,
the data suggested that it was the presence of these Cys residues, rather
than their interaction, that improved stability of the mutated PCFT.
Although the number of mutants in which Cys residues were
reintroduced in K422C-CL PCFTwas limited, a pattern of restoration of
protein expression and function emerged: (i) No single Cys residue
restored more than 25% of WT activity, although Cys229 and Cys298
were more potent than Cys21, 66 and 151. (ii) When the second Cys
residue was introduced the activity in the resulting mutant was
always increased as compared to a mutant with only one Cys residue.(ii) Maximal activity could be reached with two Cys residues as in the
case of “+C66+C298”, “C229+C328” or “C328+C397” or, in most
cases, with the addition of three Cys residues. These data suggest that
Cys residues inWT-PCFT cumulatively, though not equally, contribute
to the stability of K422C-WT PCFT. This pattern of restoration of
function by Cys residues may also be relevant to the K422E mutant
since this substitution, similar to K422C, had no impact on WT-PCFT
but decreased function and protein expression of the CL-PCFT. The
vulnerability of CL-PCFT may not only be limited to mutations at Lys
422. For instance, the R114C mutation had no functional impact on
WT-PCFT but reduced activity by ~86% in CL-PCFT (unpublished
results). Further, the vulnerability of CL-PCFT associated with
substitution of seven native cysteine residues with serine may not
be cysteine-speciﬁc; it is possible that this might also be produced by
mutations at other residues.
Lys residues often form a charge pair with negatively charged
residues that are important to the structural integrity of facilitative
transporters. For examples, charge pairs between Lys358 and Asp237,
as well as between Lys319 and Asp 240, have been identiﬁed in the
Lac transporter [25]. Data in the current report, along with our
previously results from this laboratory [21], indicate that none of the
eleven Lys residue in PCFT forms a charge pair. Eight of these residues
are not conserved; replacement of Lys378 (conserved) and Lys381
(semi-conserved) with Ala had no functional consequence [21]. Lys
422 is fully conserved but function was fully preserved even after
substitution with the negatively charged Glu in the wild-type PCFT.
The functional roles of all His and Asp residues, along with several Arg
and Glu residues, in human PCFT have been deﬁned among the
charged residues [6,7,21,26,27].Acknowledgements
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